SAGE Therapeutics Inc at Canaccord Genuity Growth Conference (Virtual) Transcript
Good day, everyone. I'm Sumant Kulkarni, a senior biotechnology analyst at Canaccord Genuity, and I'm pleased to welcome you all to our growth conference this year. Hope all of you are staying safe and enjoying your summer so far.
I'm pleased to have Sage Therapeutics with us at a very interesting time for the company. For Sage, we have CEO, Barry Greene. We'll be keeping this very interactive. So please feel free to send questions to me using your web-based interface or e-mail me at [email protected].
And with that, I'll turn it over to Barry, or we can just go straight to Q&A, depending on how he'd like to go.
Yes. Sumant, thanks for having us, and I'd like to thank the organizers for Canaccord for having us here. It's very -- as you said, it's a very exciting time for Sage. We have had a very catalyst-rich year. We see ourselves as leaders in brain health and believe that we could
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |